Altogether, the underlying mechanism involves downregulation of hnRNPA1 expression, downregulation of AR-V7 expression, antagonizes the signaling pathway of androgen receptors, and desensitizes enzalutamide-resistant prostate cancer cells to in vivo treatment with enzalutamide in mouse xenografts [145]. Here, AR is linked to prostate carcinoma.